Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINSHIP-OLE long-term danicamtiv extension in symptomatic genetic and familial dilated cardiomyopathy
NL-OMON61658Phase 3Not yet recruiting
- Sponsor
- Kardigan
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of danicamtiv in dilated cardiomyopathy (DCM), sponsored by Kardigan. Primary endpoints: Treatment-emergent adverse events and serious safety events and Abnormal clinical safety findings. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
danicamtiv
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NL-OMON61658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61658.